Development of Medical Countermeasures for Biothreat Agents, Antimicrobial-Resistant Infections an Emerging Infectious Diseases
Award Notice Posted
- Solicitation number
- HHS-NIH-NIAID-BAA2021-1
- Agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Awarded
- to AN2 Therapeutics, Inc.
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75N93022C00059 Federal contract award
Notice details come from SAM.gov. Updated .
About this opportunity
AN2 Therapeutics, Inc. was awarded a cost-reimbursement contract valued at $17,818,012 by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases on September 20, 2022 to support the development of medical countermeasures for biothreat agents, antimicrobial-resistant infections and emerging infectious diseases over the period of performance. This full and open competition contract was selected due to costs being undefined at award and will fund countermeasure development efforts.
Notice text
This cost-reimbursement contract award was made under full and open competition. This type of contract was selected because costs cannot be adequately defined at the time of contract award.
Awarded contract 75N93022C00059 to AN2 THERAPEUTICS, INC. for 17818012.00 on 2022-09-20.
Notice history
6 of 9 notices listed here. See the rest on GovTribe.
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| 2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases | National Institute of Allergy and Infectious Diseases | No set-aside | |
| Pre-Clinical Models of Infectious Diseases | National Institute of Allergy and Infectious Diseases | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity